S.N. Parsons, S.D. Luzio, D.R. Owens, SMBG Study Group. The SMBG study: a randomised controlled trial of self-monitoring of blood glucose in non-insulin treated type 2 diabetes. 53rd EASD Annual Meeting, 2017.
D.R. Owens, W. Landgraf, M. Zhang, L. Traylor, B.M. Frier, G.B. Bolli, P.D. Home. Association of fasting C-peptide levels with glycaemic efficacy and risk of hypoglycaemia in people with type 2 diabetes commencing insulin glargine 100 U/ml. 53rd EASD Annual Meeting, 2017.
B.M. Frier, W. Landgraf, M. Zhang, G.B. Bolli, D.R. Owens, P.D. Home. Association of hypoglycaemia with insulin titration and body weight in people with type 2 diabetes commencing insulin glargine 100 U/ml and achieving different HbA1c levels. 53rd EASD Annual Meeting, 2017.
R. Churm, S. Caplin, J.D. Barry, J.S. Davies, J.W. Stephens, S.L. Prior. The role of acyl ghrelin in human visceral adipose tissue in relation to the LXR-ABC pathway and the metabolic state. 53rd EASD Annual Meeting, 2017.
K. Dhatariya, S.C. Bain, R.E. Pratley, J.B. Buse, R. Simpson, L. Tarnow, M. Stellfeld, M.S. Kaltoft, K. Tornøe, on behalf of the LEADER Trial. Exploring the impact of liraglutide on diabetic foot ulcers on subjects with type 2 diabetes and increased risk of cardiovascular events: results from the LEADER trial. 53rd EASD Annual Meeting, 2017.
S. Bain, E. Araki, C. Desouza, S. Garg, L. Rose, G. Tsoukas, E. Bergan, J. Derving Karsbøl, J. DeVries. Semaglutide reduces HbA1c and body weight across baseline HbA1c subgroups in the SUSTAIN 1-5 clinical trials. 53rd EASD Annual Meeting, 2017.
F. Flacke, S. Edelman, S. Bain, C. Hasslacher, G. Charpentier, G. Vespasiani, H. Goyeau, M. Woloschak, M. Davies. Device-supported vs routine titration of insulin glargine 300 U/ml (Gla-300) in type 2 diabetes: efficacy and safety. 53rd EASD Annual Meeting, 2017.
O. Moser, O. McCarthy, R. Deere, M.L. Eckstein, S.C. Bain, H.L. Haahr, E. Zijlstra, T. Heise, R.M. Bracken. Poor glycaemic control is associated with altered physiological responses during cardio-pulmonary exercise testing in type 1 diabetes. 53rd EASD Annual Meeting, 2017.
A. Consoli, S.C. Bain, M. Davies, I. Lingvay, E.Q. Bergan, O. Hansen, T. Vilsbøll. Semaglutide provides sustained reductions in body weight over 2 years in subjects with type 2 diabetes (SUSTAIN 6). 53rd EASD Annual Meeting, 2017.
Brian M. Frier, Wolfgang Landgraf, Jason Chao, David R. Owens, Geremia B. Bolli. Comparison of Outcomes in People with T2D Treated with Insulin Glargine 100 U/mL According to Fasting Plasma Glucose Levels Achieved during Study Maintenance Period: A Pooled Analysis of Sixteen RCTs. American Diabetes Association 77th Scientific Conference, 2017.